HSANZ Free Communications 6: Aggressive lymphoma
Tracks
HSANZ
| Tuesday, October 20, 2026 |
| 8:30 AM - 10:00 AM |
Speaker
Dr Fiona Swain
Haematologist
Princess Alexandra Hospital
Divergent T-cell trajectories distinguish refractory and late-relapse DLBCL: integrated profiling of paired diagnostic and relapse biopsies
8:30 AM - 8:45 AM
Dr Joshua Tobin
Staff Specialist, Haematologist
Princess Alexandra Hospital
Ibrutinib, rituximab, valaciclovir and third-party EBV-specific virus specific T-lymphocytes for EBV-positive immunosuppression-associated lymphoproliferative disorders: Results of the ALLG TREBL1 phase 1 investigator-initiated trial
8:45 AM - 9:00 AM
Dr Zachary Hawula
Postdoctoral Research Fellow
University of Queensland
Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling
9:00 AM - 9:15 AM
Dr Cale Burge
Cellular Therapies Fellow
Royal Prince Alfred Hospital
Evolving bridging strategies for CD19 CAR T-cell therapy in aggressive B-cell lymphoma: a 7-year single-centre experience
9:15 AM - 9:30 AM
Dr Melinda Burgess
Post Doc
Fraser Institute / University of Queensland
Divergent immune ecosystems in immune-privileged diffuse large B-cell lymphomas
9:30 AM - 9:45 AM
Dr Sean McKeague
Haematologist
Royal Brisbane & Women's Hospital
Incidence, predictors and impact of immune effector cell associated haematotoxicity (ICAHT) post Axi-cel for LBCL: An analysis from the AusCART consortium
9:45 AM - 10:00 AM
